TSL.L Regulatory News (TSL)

4 Jul 2006 14:18

Tissue Science Laboratories PLC04 July 2006 4 July 2006 Tissue Science Laboratories PLC Result of Annual General Meeting Tissue Science Laboratories plc, the medical devices company specialising inhuman tissue replacement and repair, held its Annual General Meeting today atwhich all resolutions referred to in the Notice of Annual General Meeting werepassed. -Ends- Enquiries: TSL plc Tel: 01252 333 002Martin Hunt, Chief Executive OfficerDavid Jennings, Finance Director Hogarth PR Tel: 020 7357 9477Melanie Toyne Sewell / Sarah Richardson Notes to Editors Background on TSL Founded in 1995, with headquarters in Aldershot, Hampshire, TSL is a medicaltechnology company specialising in tissue repair and replacement with aproprietary sheet product, derived from porcine dermis, called Permacol(R). TSLhas launched successfully different formulations of the product and built adevelopment pipeline that addresses the large and fast growing surgical implantmarket. The Company floated in November 2001 and is listed on the AlternativeInvestment Market (LSE: TSL). TSL has a family of products based on the same core technology. Each producthas been adapted, with unique properties, to make it suitable for use indifferent applications, including urology/gynaecology, complex and recurrenthernia repair, shoulder rotator cuff repair and head and face repair andreconstruction. The Company has signed distribution agreements with CR Bard Inc(urology/gynaecology - worldwide), Zimmer Inc (orthopaedic - worldwide) andPorex Surgical Inc (head and face - US and Canada). Further variations of thesheet and injectable forms of Permacol(R) are being developed. For moreinformation on TSL, please visit the website at www.tissuescience.com. This information is provided by RNS The company news service from the London Stock Exchange